title: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
abstract: The presence of neuroendocrine (NE) differentiation in the context of predominantly exocrine prostate cancer may play a key role in androgen-independent tumor growth. The prognostic significance of plasma chromogranin A (CgA) was assessed in a series of consecutive prostate cancer patients with hormone-refractory disease. One hundred and eight patients with newly diagnosed hormone-refractory prostate cancer entered the study. Plasma CgA levels and other biochemical parameters, such as serum prostate specific antigen, serum alkaline phosphatase, serum lactate dehydrogenase, serum albumin and hemoglobin concentration, were measured at baseline (i.e. when hormone refractoriness occurred) and their prognostic role was evaluated together with patient performance status, Gleason score (at diagnosis of prostate cancer) and the presence of visceral metastases. Furthermore, plasma CgA was prospectively evaluated in 50 patients undergoing chemotherapy. At baseline, 45 patients (43.3%) showed elevated CgA values. Plasma CgA negatively correlated with survival, either in univariate analysis (P=0.008) or in multivariate analysis, after adjusting for previously mentioned prognostic parameters (P<0.05). In the patient subset undergoing chemotherapy, median CgA (range) values were 13.3 (3.0-141.0) U/l at baseline, 19.1 (3.0-486.0) U/l after 3 months, 20.8 (3.0-702.0) U/l after 6 months and 39.4 (3.0-414.0) U/l after 9 months (P<0.01). The corresponding supranormal rates were 17/50 (34%), 23/50 (46%), 26/50 (52%) and 34/50 (68%) respectively (P<0.005). Elevated plasma CgA levels are frequently observed in prostate cancer patients with hormone-refractory disease and correlate with poor prognosis. NE differentiation in hormone-refractory patients is a time-dependent phenomenon and is not influenced by conventional antineoplastic treatments.
authors.affiliation: Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Berruti
authors.forename: A
authors.initials: A
authors.lastname: Mosca
authors.forename: M
authors.initials: M
authors.lastname: Tucci
authors.forename: C
authors.initials: C
authors.lastname: Terrone
authors.forename: M
authors.initials: M
authors.lastname: Torta
authors.forename: R
authors.initials: R
authors.lastname: Tarabuzzi
authors.forename: L
authors.initials: L
authors.lastname: Russo
authors.forename: C
authors.initials: C
authors.lastname: Cracco
authors.forename: E
authors.initials: E
authors.lastname: Bollito
authors.forename: R M
authors.initials: RM
authors.lastname: Scarpa
authors.forename: A
authors.initials: A
authors.lastname: Angeli
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary; D002454:Cell Differentiation; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008113:Liver Neoplasms / Q000097:blood / Q000556:secondary; D008175:Lung Neoplasms / Q000097:blood / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D015996:Survival Rate
chemical_list: D000418:Albumins; D014408:Biomarkers, Tumor; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins; D006454:Hemoglobins; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase; D017430:Prostate-Specific Antigen